COVID ups risks of dementia, cognitive impairment, and decline in older survivorsSadly and not surprisingly, the science media is reporting that the neurological impact of covid 19 is showing increased levels of cognitive decline worldwide. Older adults are having to cope with damage to their lungs and central nervous system. The study noted that the telephone survey measures used were limited in identifying more specific challenges and likely underestimate the size of the problem due to having excluded subjects with any family history of dementia. The global dementia care burden is likely to be greater as a result of the COVID-19 pandemic and so there is even greater need to rapid intervention now that can be easily, safely and cost effectively deployed. Researchers and clinicians at Quietmind Foundation, Neuronic Devices Ltd (Neuronic.online), Baylor Research Institute and the Biophotonic and Neuroimaging Lab•UTexas-Arlington are collaborating to show the effectiveness of self-administered, transcranial infrared light-based therapy to reduce dementia's cognitive and behavioral symptoms.
The Neuradiant 1070 4Q technology that's being released this month by Neuronic Devices Ltd. (see Neuronic.online) is a resource that can address the debilitating impact of COVID 19 on the brain by increasing cortical perfusion and ATP production by stimulating cytochrome c oxidase and improving blood vessel flexibility. In addition, the new independent 4 -quadrant control of pulse frequency allows for renormalization of dysregulated brain network connectivity using the light pulsations to directly changes in EEG activity. https://arstechnica.com/science/2022/03/covid-ups-risks-of-dementia-cognitive-impairment-and-decline-in-older-survivors/
0 Comments
Mental disorders in early life are associated with a significantly increased risk of dementia in later years.
|
1pbm_depression_anxiety_and_cognition.pdf | |
File Size: | 420 kb |
File Type: |

pbm_-_normal_people.pdf | |
File Size: | 178 kb |
File Type: |
Devices based on these findings are now available under clinical supervision through Quietmind Foundation. Inquiries should be directed to Marvin Berman PhD 610-940-0488
Read the UVA article here.
QMF News
Our team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general.
Archives
June 2025
March 2025
January 2025
December 2024
October 2024
July 2024
March 2024
June 2023
May 2023
April 2023
March 2023
February 2023
January 2023
December 2022
November 2022
October 2022
August 2022
July 2022
June 2022
April 2022
March 2022
February 2022
January 2022
November 2021
October 2021
September 2021
August 2021
July 2021
June 2021
May 2021
April 2021
February 2021
January 2021
December 2020
November 2020
October 2020
September 2020
August 2020
July 2020
June 2020
May 2020
April 2020
March 2020
February 2020
January 2020
December 2019
October 2019
September 2019
August 2019
June 2019
May 2019
April 2019
February 2019
January 2019
December 2018
November 2018
October 2018
September 2018
August 2018
July 2018
April 2018
March 2018
November 2017
October 2017
September 2017
August 2017
July 2017
May 2017
Categories
All
Alzheimer's
Biofeedback
Breathing Training
Dementia
Dementia Treatment
Drug Free Anxiety Treatment
Infrared Light
Light Therapy
Neurofeedback
Neurotherapy
Panic Disorder
Photobiomodulation
Relaxation
TBI Treatment
Therapy